Four HSC Winnipeg researchers awarded $4.25M in CIHR grants
Winnipeg Regional Health Authority
Friday, December 9, 2016
Four new research projects will be led by four Health Sciences Centre (HSC) Winnipeg-affiliated researchers, thanks to $4.25 million in funding from the Canadian Institutes of Health Research (CIHR).
"On behalf of the Research Department, I congratulate HSC Winnipeg-based researchers for their success in attaining CIHR funding," said Dr. Eric Jacobsohn, Medical Director of Research at HSC Winnipeg, after today's announcement at the University of Manitoba Bannatyne Campus. "The research done at HSC Winnipeg has the potential to transform the lives of many patients."
HSC Winnipeg is a leader in Canadian health research.
The CIHR recipients and their projects are:
Dr. Chris Anderson, Director, Neuroscience Research Program, HSC Winnipeg; Professor, Department of Pharmacology and Therapeutics, University of Manitoba
- Awarded $100,000 for a one-year study to explore why brain cells die or degrade in patients with neurological or psychiatric disorders, aiming to improve treatments in these areas.
Dr. Julie Ho, transplant physician, HSC Winnipeg; Associate Professor, Departments of Internal Medicine & Immunology, University of Manitoba
- Awarded $2.66 million for a five-year clinical trial to study early rejection markers in kidney recipients, aiming to develop a new non-invasive test to improve transplant health.
Dr. Richard Keijzer, pediatric surgeon, HSC Winnipeg Children's Hospital and Children's Hospital Research Institute of Manitoba; Assistant Professor, Departments of Surgery, Pediatrics and Child Health, & Physiology, University of Manitoba
- Awarded $0.64 million for a four-year study to better understand abnormal lung development in babies born with damaged diaphragms, leading to better lung development therapies.
Dr. Donald Miller, Professor, Department of Pharmacology and Therapeutics, University of Manitoba
- Awarded $0.85 million for a 5-year international multidisciplinary research study to explore new ways of getting drugs across the blood-brain barrier, targeting and killing tumour cells.